Cross-talk between HIF and p53 as mediators of molecular responses to physiological and genotoxic stresses

Molecular Cancer

Volumn 12, Issue 1, 2013, Pages

  Obacz, Joanna ^a,b   Pastorekova, Silvia ^b   Vojtesek, Borek ^a   Hrstka, Roman ^a  

^a MASARYK MEMORIAL CANCER INSTITUTE   (Czech Republic)

^b INSTITUTE OF VIROLOGY   (Slovakia)

Author keywords

Cancer; DNA damage; HIF 1; Hypoxia; p53

Indexed keywords

HYPOXIA INDUCIBLE FACTOR; PROTEIN P53;

APOPTOSIS; CANCER GROWTH; CELL CYCLE REGULATION; CELL METABOLISM; CELLULAR STRESS RESPONSE; DNA DAMAGE; GENOTOXIC STRESS; MOLECULAR BIOLOGY; PHYSIOLOGICAL PROCESS; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION; STRESS; TREATMENT OUTCOME;

ANIMALS; CARCINOGENESIS; CELL HYPOXIA; DNA DAMAGE; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; NEOPLASMS; STRESS, PHYSIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84883750997     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-12-93     Document Type: Review

References (126)

1. Liao D, Johnson RS. Hypoxia: a key regulator of angiogenesis in cancer. Cancer Metastasis Rev 2007, 26(2):281-290. 10.1007/s10555-007-9066-y, 17603752.
2. Ivan M, Kondo K, Yang H, Kim W, Valiando J, Ohh M, Salic A, Asara JM, Lane WS, Kaelin WG. HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science 2001, 292(5516):464-468. 10.1126/science.1059817, 11292862.
3. Lando D, Peet DJ, Gorman JJ, Whelan DA, Whitelaw ML, Bruick RK. FIH-1 is an asparaginyl hydroxylase enzyme that regulates the transcriptional activity of hypoxia-inducible factor. Genes Dev 2002, 16(12):1466-1471. 10.1101/gad.991402, 186346, 12080085.
4. Keith B, Johnson RS, Simon MC. HIF1α and HIF2α: sibling rivalry in hypoxic tumour growth and progression. Nat Rev Cancer 2012, 12(1):9-22.
5. Uchida T, Rossignol F, Matthay MA, Mounier R, Couette S, Clottes E, Clerici C. Prolonged hypoxia differentially regulates hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha expression in lung epithelial cells: implication of natural antisense HIF-1alpha. J Biol Chem 2004, 279(15):14871-14878. 10.1074/jbc.M400461200, 14744852.
6. Ratcliffe PJ, O'Rourke JF, Maxwell PH, Pugh CW. Oxygen sensing, hypoxia-inducible factor-1 and the regulation of mammalian gene expression. J Exp Biol 1998, 201(Pt 8):1153-1162.
7. Fernandez-Sanchez R, Berzal S, Sanchez-Nino MD, Neria F, Goncalves S, Calabia O, Tejedor A, Calzada MJ, Caramelo C, Deudero JJ, et al. AG490 Promotes HIF-1alpha accumulation by inhibiting its hydroxylation. Curr Med Chem 2012, 19(23):4014-4023. 10.2174/092986712802002554, 22709000.
8. Altun M, Zhao B, Velasco K, Liu H, Hassink G, Paschke J, Pereira T, Lindsten K. Ubiquitin-specific protease 19 (USP19) regulates hypoxia-inducible factor 1α (HIF-1α) during hypoxia. J Biol Chem 2012, 287(3):1962-1969. 10.1074/jbc.M111.305615, 3265877, 22128162.
9. Xu J, Wang B, Xu Y, Sun L, Tian W, Shukla D, Barod R, Grillari J, Grillari-Voglauer R, Maxwell PH, et al. Epigenetic regulation of HIF-1α in renal cancer cells involves HIF-1α/2α binding to a reverse hypoxia-response element. Oncogene 2012, 31(8):1065-1072. 10.1038/onc.2011.305, 21841824.
10. Dimova EY, Michiels C, Kietzmann T. Kinases as upstream regulators of the HIF system: their emerging potential as anti-cancer drug targets. Curr Pharm Des 2009, 15(33):3867-3877. 10.2174/138161209789649358, 19671044.
11. Pastorek J, Pastorekova S, Callebaut I, Mornon JP, Zelnik V, Opavsky R, Zat'ovicova M, Liao S, Portetelle D, Stanbridge EJ, et al. Cloning and characterization of MN, a human tumor-associated protein with a domain homologous to carbonic anhydrase and a putative helix-loop-helix DNA binding segment. Oncogene 1994, 9(10):2877-2888.
12. Wykoff CC, Beasley NJ, Watson PH, Turner KJ, Pastorek J, Sibtain A, Wilson GD, Turley H, Talks KL, Maxwell PH, et al. Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Res 2000, 60(24):7075-7083.
13. Ditte P, Dequiedt F, Svastova E, Hulikova A, Ohradanova-Repic A, Zatovicova M, Csaderova L, Kopacek J, Supuran CT, Pastorekova S, et al. Phosphorylation of carbonic anhydrase IX controls its ability to mediate extracellular acidification in hypoxic tumors. Cancer Res 2011, 71(24):7558-7567. 10.1158/0008-5472.CAN-11-2520, 22037869.
14. Svastova E, Hulikova A, Rafajova M, Zat'ovicova M, Gibadulinova A, Casini A, Cecchi A, Scozzafava A, Supuran CT, Pastorek J, et al. Hypoxia activates the capacity of tumor-associated carbonic anhydrase IX to acidify extracellular pH. FEBS Lett 2004, 577(3):439-445. 10.1016/j.febslet.2004.10.043, 15556624.
15. Chiche J, Ilc K, Brahimi-Horn MC, Pouyssegur J. Membrane-bound carbonic anhydrases are key pH regulators controlling tumor growth and cell migration. Adv Enzyme Regul 2010, 50(1):20-33. 10.1016/j.advenzreg.2009.10.005, 19895836.
16. Swietach P, Wigfield S, Cobden P, Supuran CT, Harris AL, Vaughan-Jones RD. Tumor-associated carbonic anhydrase 9 spatially coordinates intracellular pH in three-dimensional multicellular growths. J Biol Chem 2008, 283(29):20473-20483. 10.1074/jbc.M801330200, 18482982.
17. Svastova E, Witarski W, Csaderova L, Kosik I, Skvarkova L, Hulikova A, Zatovicova M, Barathova M, Kopacek J, Pastorek J, et al. Carbonic anhydrase IX interacts with bicarbonate transporters in lamellipodia and increases cell migration via its catalytic domain. J Biol Chem 2012, 287(5):3392-3402. 10.1074/jbc.M111.286062, 3270993, 22170054.
18. Buchler P, Reber HA, Buchler M, Shrinkante S, Buchler MW, Friess H, Semenza GL, Hines OJ. Hypoxia-inducible factor 1 regulates vascular endothelial growth factor expression in human pancreatic cancer. Pancreas 2003, 26(1):56-64. 10.1097/00006676-200301000-00010, 12499918.
19. Forsythe JA, Jiang BH, Iyer NV, Agani F, Leung SW, Koos RD, Semenza GL. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 1996, 16(9):4604-4613. 231459, 8756616.
20. Wan J, Chai H, Yu Z, Ge W, Kang N, Xia W, Che Y. HIF-1α effects on angiogenic potential in human small cell lung carcinoma. J Exp Clin Cancer Res 2011, 30(1):77. 10.1186/1756-9966-30-77, 3174873, 21843314.
21. Brahimi-Horn MC, Bellot G, Pouyssegur J. Hypoxia and energetic tumour metabolism. Curr Opin Genet Dev 2011, 21(1):67-72. 10.1016/j.gde.2010.10.006, 21074987.
22. Lum JJ, Bui T, Gruber M, Gordan JD, DeBerardinis RJ, Covello KL, Simon MC, Thompson CB. The transcription factor HIF-1alpha plays a critical role in the growth factor-dependent regulation of both aerobic and anaerobic glycolysis. Genes Dev 2007, 21(9):1037-1049. 10.1101/gad.1529107, 1855230, 17437992.
23. Zhang H, Gao P, Fukuda R, Kumar G, Krishnamachary B, Zeller KI, Dang CV, Semenza GL. HIF-1 inhibits mitochondrial biogenesis and cellular respiration in VHL-deficient renal cell carcinoma by repression of C-MYC activity. Cancer Cell 2007, 11(5):407-420. 10.1016/j.ccr.2007.04.001, 17482131.
24. Marin-Hernandez A, Gallardo-Perez JC, Ralph SJ, Rodriguez-Enriquez S, Moreno-Sanchez R. HIF-1alpha modulates energy metabolism in cancer cells by inducing over-expression of specific glycolytic isoforms. Mini Rev Med Chem 2009, 9(9):1084-1101. 10.2174/138955709788922610, 19689405.
25. Semenza GL. Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene 2010, 29(5):625-634. 10.1038/onc.2009.441, 2969168, 19946328.
26. Rohwer N, Cramer T. Hypoxia-mediated drug resistance: novel insights on the functional interaction of HIFs and cell death pathways. Drug Resist Updat 2011, 14(3):191-201. 10.1016/j.drup.2011.03.001, 21466972.
27. Riley T, Sontag E, Chen P, Levine A. Transcriptional control of human p53-regulated genes. Nat Rev Mol Cell Biol 2008, 9(5):402-412. 10.1038/nrm2395, 18431400.
28. Green DR, Kroemer G. Cytoplasmic functions of the tumour suppressor p53. Nature 2009, 458(7242):1127-1130. 10.1038/nature07986, 2814168, 19407794.
29. Feng Z, Levine AJ. The regulation of energy metabolism and the IGF-1/mTOR pathways by the p53 protein. Trends Cell Biol 2010, 20(7):427-434. 10.1016/j.tcb.2010.03.004, 2921989, 20399660.
30. Wu X, Bayle JH, Olson D, Levine AJ. The p53-mdm-2 autoregulatory feedback loop. Genes Dev 1993, 7(7A):1126-1132. 10.1101/gad.7.7a.1126, 8319905.
31. Prives C. Signaling to p53: breaking the MDM2-p53 circuit. Cell 1998, 95(1):5-8. 10.1016/S0092-8674(00)81774-2, 9778240.
32. Chen L, Li Z, Zwolinska AK, Smith MA, Cross B, Koomen J, Yuan Z-M, Jenuwein T, Marine J-C, Wright KL, et al. MDM2 Recruitment of lysine methyltransferases regulates p53 transcriptional output. EMBO J 2010, 29(15):2538-2552. 10.1038/emboj.2010.140, 2928696, 20588255.
33. Candeias MM, Malbert-Colas L, Powell DJ, Daskalogianni C, Maslon MM, Naski N, Bourougaa K, Calvo F, Fahraeus R. P53 MRNA controls p53 activity by managing Mdm2 functions. Nat Cell Biol 2008, 10(9):1098-1105. 10.1038/ncb1770, 19160491.
34. Gajjar M, Candeias MM, Malbert-Colas L, Mazars A, Fujita J, Olivares-Illana V, Fahraeus R. The p53 mRNA-Mdm2 interaction controls Mdm2 nuclear trafficking and is required for p53 activation following DNA damage. Cancer Cell 2012, 21(1):25-35. 10.1016/j.ccr.2011.11.016, 22264786.
35. Feng Z, Zhang H, Levine AJ, Jin S. The coordinate regulation of the p53 and mTOR pathways in cells. Proc Natl Acad Sci USA 2005, 102(23):8204-8209. 10.1073/pnas.0502857102, 1142118, 15928081.
36. Sen N, Satija YK, Das S. p53 and metabolism: old player in a new game. Transcription 2012, 3(3):119-123. 10.4161/trns.20094, 3616081, 22771946.
37. Hublarova P, Greplova K, Holcakova J, Vojtesek B, Hrstka R. Switching p53-dependent growth arrest to apoptosis via the inhibition of DNA damage-activated kinases. Cell Mol Biol Lett 2010, 15(3):473-484. 10.2478/s11658-010-0021-5, 20526748.
38. Chen BP, Wolfgang CD, Hai T. Analysis of ATF3, a transcription factor induced by physiological stresses and modulated by gadd153/Chop10. Mol Cell Biol 1996, 16(3):1157-1168. 231098, 8622660.
39. Tanaka Y, Nakamura A, Morioka MS, Inoue S, Tamamori-Adachi M, Yamada K, Taketani K, Kawauchi J, Tanaka-Okamoto M, Miyoshi J, et al. Systems analysis of ATF3 in stress response and cancer reveals opposing effects on pro-apoptotic genes in p53 pathway. PLoS One 2011, 6(10):e26848. 10.1371/journal.pone.0026848, 3202577, 22046379.
40. Zhang X-P, Liu F, Wang W. Two-phase dynamics of p53 in the DNA damage response. Proc Natl Acad Sci USA 2011, 108(22):8990-8995. 10.1073/pnas.1100600108, 3107314, 21576488.
41. Takekawa M, Adachi M, Nakahata A, Nakayama I, Itoh F, Tsukuda H, Taya Y, Imai K. p53-Inducible wip1 phosphatase mediates a negative feedback regulation of p38 MAPK-p53 signaling in response to UV radiation. EMBO J 2000, 19(23):6517-6526. 10.1093/emboj/19.23.6517, 305857, 11101524.
42. Tasdemir E, Maiuri MC, Galluzzi L, Vitale I, Djavaheri-Mergny M, D'Amelio M, Criollo A, Morselli E, Zhu C, Harper F, et al. Regulation of autophagy by cytoplasmic p53. Nat Cell Biol 2008, 10(6):676-687. 10.1038/ncb1730, 2676564, 18454141.
43. Prives C, Hall PA. The p53 pathway. J Pathol 1999, 187(1):112-126. 10.1002/(SICI)1096-9896(199901)187:1<112::AID-PATH250>3.0.CO;2-3, 10341712.
44. Muller P, Hrstka R, Coomber D, Lane DP, Vojtesek B. Chaperone-dependent stabilization and degradation of p53 mutants. Oncogene 2008, 27(24):3371-3383. 10.1038/sj.onc.1211010, 18223694.
45. Royds JA, Dower SK, Qwarnstrom EE, Lewis CE. Response of tumour cells to hypoxia: role of p53 and NFkB. Mol Pathol 1998, 51(2):55-61. 10.1136/mp.51.2.55, 395611, 9713587.
46. Graeber TG, Peterson JF, Tsai M, Monica K, Fornace AJ, Giaccia AJ. Hypoxia induces accumulation of p53 protein, but activation of a G1-phase checkpoint by low-oxygen conditions is independent of p53 status. Mol Cell Biol 1994, 14(9):6264-6277. 10.1128/MCB.14.9.6264, 359153, 8065358.
47. Hammond EM, Denko NC, Dorie MJ, Abraham RT, Giaccia AJ. Hypoxia links ATR and p53 through replication arrest. Mol Cell Biol 2002, 22(6):1834-1843. 10.1128/MCB.22.6.1834-1843.2002, 135616, 11865061.
48. Hubert A, Paris S, Piret JP, Ninane N, Raes M, Michiels C. Casein kinase 2 inhibition decreases hypoxia-inducible factor-1 activity under hypoxia through elevated p53 protein level. J Cell Sci 2006, 119(Pt 16):3351-3362.
49. Zhang L, Hill RP. Hypoxia enhances metastatic efficiency by up-regulating Mdm2 in KHT cells and increasing resistance to apoptosis. Cancer Res 2004, 64(12):4180-4189. 10.1158/0008-5472.CAN-03-3038, 15205329.
50. Wouters A, Pauwels B, Lambrechts HAJ, Pattyn GGO, Ides J, Baay M, Meijnders P, Dewilde S, Vermorken JB, Lardon F. Chemoradiation interactions under reduced oxygen conditions: cellular characteristics of an in vitro model. Cancer Lett 2009, 286(2):180-188. 10.1016/j.canlet.2009.05.026, 19540039.
51. Sermeus A, Michiels C. Reciprocal influence of the p53 and the hypoxic pathways. Cell Death Dis 2011, 2:e164. 10.1038/cddis.2011.48, 3122125, 21614094.
52. Suzuki H, Tomida A, Tsuruo T. Dephosphorylated hypoxia-inducible factor 1alpha as a mediator of p53-dependent apoptosis during hypoxia. Oncogene 2001, 20(41):5779-5788. 10.1038/sj.onc.1204742, 11593383.
53. An WG, Kanekal M, Simon MC, Maltepe E, Blagosklonny MV, Neckers LM. Stabilization of wild-type p53 by hypoxia-inducible factor 1alpha. Nature 1998, 392(6674):405-408. 10.1038/32925, 9537326.
54. Achison M, Hupp TR. Hypoxia attenuates the p53 response to cellular damage. Oncogene 2003, 22(22):3431-3440. 10.1038/sj.onc.1206434, 12776195.
55. Cosse J-P, Sermeus A, Vannuvel K, Ninane N, Raes M, Michiels C. Differential effects of hypoxia on etoposide-induced apoptosis according to the cancer cell lines. Mol Cancer 2007, 6:61. 2099441, 17894897.
56. Kaluzova M, Kaluz S, Lerman MI, Stanbridge EJ. DNA damage is a prerequisite for p53-mediated proteasomal degradation of HIF-1alpha in hypoxic cells and downregulation of the hypoxia marker carbonic anhydrase IX. Mol Cell Biol 2004, 24(13):5757-5766. 10.1128/MCB.24.13.5757-5766.2004, 480909, 15199132.
57. Nardinocchi L, Puca R, D'Orazi G. HIF-1 alpha antagonizes p53-mediated apoptosis by triggering HIPK2 degradation. Aging-Us 2011, 3(1):33-43.
58. D'Orazi G, Cecchinelli B, Bruno T, Manni I, Higashimoto Y, Saito S, Gostissa M, Coen S, Marchetti A, Del Sal G, et al. Homeodomain-interacting protein kinase-2 phosphorylates p53 at Ser 46 and mediates apoptosis. Nat Cell Biol 2002, 4(1):11-19. 10.1038/ncb714, 11780126.
59. Nardinocchi L, Puca R, Sacchi A, Rechavi G, Givol D, D'Orazi G. Targeting hypoxia in cancer cells by restoring homeodomain interacting protein-kinase 2 and p53 activity and suppressing HIF-1 alpha. PLoS One 2009, 4(8):e6819. 10.1371/journal.pone.0006819, 2729407, 19714248.
60. Gogna R, Madan E, Kuppusamy P, Pati U. Chaperoning of mutant p53 protein by wild-type p53 protein causes hypoxic tumor regression. J Biol Chem 2012, 287(4):2907-2914. 10.1074/jbc.M111.317354, 3268447, 22147694.
61. Madan E, Gogna R, Pati U. p53 Ser15 Phosphorylation disrupts the p53-RPA70 complex and induces RPA70-mediated DNA repair in hypoxia. Biochem J 2012, 443(3):811-820. 10.1042/BJ20111627, 22288499.
62. Thomas DD, Espey MG, Ridnour LA, Hofseth LJ, Mancardi D, Harris CC, Wink DA. Hypoxic inducible factor 1alpha, extracellular signal-regulated kinase, and p53 are regulated by distinct threshold concentrations of nitric oxide. Proc Natl Acad Sci USA 2004, 101(24):8894-8899. 10.1073/pnas.0400453101, 428443, 15178764.
63. Warburg O. On the origin of cancer cells. Science 1956, 123(3191):309-314. 10.1126/science.123.3191.309, 13298683.
64. Yalcin A, Telang S, Clem B, Chesney J. Regulation of glucose metabolism by 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatases in cancer. Exp Mol Pathol 2009, 86(3):174-179. 10.1016/j.yexmp.2009.01.003, 19454274.
65. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009, 324(5930):1029-1033. 10.1126/science.1160809, 2849637, 19460998.
66. Hsu PP, Sabatini DM. Cancer cell metabolism: Warburg and beyond. Cell 2008, 134(5):703-707. 10.1016/j.cell.2008.08.021, 18775299.
67. Ferguson EC, Rathmell JC. New roles for pyruvate kinase M2: working out the Warburg effect. Trends Biochem Sci 2008, 33(8):359-362. 10.1016/j.tibs.2008.05.006, 2590867, 18603432.
68. Hommes FA, Everts RS. Particulate and free hexokinase in fetal rat liver. Biol Neonate 1978, 33(3-4):193-200.
69. Kuhajda FP. Fatty-acid synthase and human cancer: new perspectives on its role in tumor biology. Nutrition 2000, 16(3):202-208. 10.1016/S0899-9007(99)00266-X, 10705076.
70. Migita T, Narita T, Nomura K, Miyagi E, Inazuka F, Matsuura M, Ushijima M, Mashima T, Seimiya H, Satoh Y, et al. ATP citrate lyase: activation and therapeutic implications in non-small cell lung cancer. Cancer Res 2008, 68(20):8547-8554. 10.1158/0008-5472.CAN-08-1235, 18922930.
71. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, Kos I, Batinic-Haberle I, Jones S, Riggins GJ, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med 2009, 360(8):765-773. 10.1056/NEJMoa0808710, 2820383, 19228619.
72. Young CD, Anderson SM. Sugar and fat - that's where it's at: metabolic changes in tumors. Breast Cancer Res 2008, 10(1):202. 10.1186/bcr1852, 2374962, 18304378.
73. Mentis A-FA, Kararizou E. Metabolism and cancer: an up-to-date review of a mutual connection. Asian Pac J Cancer Prev 2010, 11(6):1437-1444.
74. Israel M, Schwartz L. The metabolic advantage of tumor cells. Mol Cancer 2011, 10:70. 10.1186/1476-4598-10-70, 3118193, 21649891.
75. Munoz-Pinedo C, El Mjiyad N, Ricci JE. Cancer metabolism: current perspectives and future directions. Cell Death Dis 2012, 3:e248. 10.1038/cddis.2011.123, 3270265, 22237205.
76. Guccini I, Serio D, Condo I, Rufini A, Tomassini B, Mangiola A, Maira G, Anile C, Fina D, Pallone F, et al. Frataxin participates to the hypoxia-induced response in tumors. Cell Death Dis 2011, 2:e123. 10.1038/cddis.2011.5, 3101705, 21368894.
77. Selak MA, Armour SM, MacKenzie ED, Boulahbel H, Watson DG, Mansfield KD, Pan Y, Simon MC, Thompson CB, Gottlieb E. Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. Cancer Cell 2005, 7(1):77-85. 10.1016/j.ccr.2004.11.022, 15652751.
78. Kawauchi K, Araki K, Tobiume K, Tanaka N. p53 Regulates glucose metabolism through an IKK-NF-kappaB pathway and inhibits cell transformation. Nat Cell Biol 2008, 10(5):611-618. 10.1038/ncb1724, 18391940.
79. Wanka C, Brucker DP, Bähr O, Ronellenfitsch M, Weller M, Steinbach JP, Rieger J. Synthesis of cytochrome c oxidase 2: a p53-dependent metabolic regulator that promotes respiratory function and protects glioma and colon cancer cells from hypoxia-induced cell death. Oncogene 2012, 31(33):3764-3776. 10.1038/onc.2011.530, 22120717.
80. White E, Karp C, Strohecker AM, Guo YX, Mathew R. Role of autophagy in suppression of inflammation and cancer. Curr Opin Cell Biol 2010, 22(2):212-217. 10.1016/j.ceb.2009.12.008, 2857707, 20056400.
81. Mazure NM, Pouyssegur J. Hypoxia-induced autophagy: cell death or cell survival?. Curr Opin Cell Biol 2010, 22(2):177-180. 10.1016/j.ceb.2009.11.015, 20022734.
82. Martinez-Outschoorn UE, Trimmer C, Lin Z, Whitaker-Menezes D, Chiavarina B, Zhou J, Wang CW, Pavlides S, Martinez-Cantarin MP, Capozza F, et al. Autophagy in cancer associated fibroblasts promotes tumor cell survival role of hypoxia, HIF1 induction and NF kappa B activation in the tumor stromal microenvironment. Cell Cycle 2010, 9(17):3515-3533. 10.4161/cc.9.17.12928, 3047617, 20855962.
83. Crighton D, Wilkinson S, O'Prey J, Syed N, Smith P, Harrison PR, Gasco M, Garrone O, Crook T, Ryan KM. DRAM, a p53-induced modulator of autophagy, is critical for apoptosis. Cell 2006, 126(1):121-134. 10.1016/j.cell.2006.05.034, 16839881.
84. Xu-Monette ZY, Young KH. The TP53 tumor suppressor and autophagy in malignant lymphoma. Autophagy 2012, 8(5):842-845. 10.4161/auto.19703, 3378422, 22498492.
85. Boya P, Gonzalez-Polo RA, Casares N, Perfettini JL, Dessen P, Larochette N, Metivier D, Meley D, Souquere S, Yoshimori T, et al. Inhibition of macroautophagy triggers apoptosis. Mol Cell Biol 2005, 25(3):1025-1040. 10.1128/MCB.25.3.1025-1040.2005, 543994, 15657430.
86. Tasdemir E, Maiuri MC, Galluzzi L, Vitale I, Djavaheri-Mergny M, D'Amelio M, Criollo A, Morselli E, Zhu CL, Harper F, et al. Regulation of autophagy by cytoplasmic p53. Nat Cell Biol 2008, 10(6):676-687. 10.1038/ncb1730, 2676564, 18454141.
87. Naves T, Jawhari S, Jauberteau MO, Ratinaud MH, Verdier M. Autophagy takes place in mutated p53 neuroblastoma cells in response to hypoxia mimetic CoCl2. Biochem Pharmacol 2013, 85(8):1153-1161. 10.1016/j.bcp.2013.01.022, 23380477.
88. Leontieva OV, Natarajan V, Demidenko ZN, Burdelya LG, Gudkov AV, Blagosklonny MV. Hypoxia suppresses conversion from proliferative arrest to cellular senescence. Proc Natl Acad Sci USA 2012, 109(33):13314-13318. 10.1073/pnas.1205690109, 3421205, 22847439.
89. Dos Santos F, Andrade PZ, Boura JS, Abecasis MM, da Silva CL, Cabral JM. Ex vivo expansion of human mesenchymal stem cells: a more effective cell proliferation kinetics and metabolism under hypoxia. J Cell Physiol 2010, 223(1):27-35.
90. Tsai CC, Chen YJ, Yew TL, Chen LL, Wang JY, Chiu CH, Hung SC. Hypoxia inhibits senescence and maintains mesenchymal stem cell properties through down-regulation of E2A-p21 by HIF-TWIST. Blood 2011, 117(2):459-469. 10.1182/blood-2010-05-287508, 20952688.
91. Welford SM, Giaccia AJ. Hypoxia and senescence: the impact of oxygenation on tumor suppression. Mol Cancer Res 2011, 9(5):538-544. 10.1158/1541-7786.MCR-11-0065, 3096743, 21385881.
92. Chen Q, Fischer A, Reagan JD, Yan LJ, Ames BN. Oxidative DNA damage and senescence of human diploid fibroblast cells. Proc Natl Acad Sci USA 1995, 92(10):4337-4341. 10.1073/pnas.92.10.4337, 41939, 7753808.
93. Capparelli C, Whitaker-Menezes D, Guido C, Balliet R, Pestell TG, Howell A, Sneddon S, Pestell RG, Martinez-Outschoorn U, Lisanti MP, et al. CTGF drives autophagy, glycolysis and senescence in cancer-associated fibroblasts via HIF1 activation, metabolically promoting tumor growth. Cell Cycle 2012, 11(12):2272-2284. 10.4161/cc.20717, 3383589, 22684333.
94. Welford SM, Dorie MJ, Li X, Haase VH, Giaccia AJ. Renal oxygenation suppresses VHL loss-induced senescence that is caused by increased sensitivity to oxidative stress. Mol Cell Biol 2010, 30(19):4595-4603. 10.1128/MCB.01618-09, 2950534, 20679489.
95. Dulic V. Senescence regulation by mTOR. Methods Mol Biol 2013, 965:15-35. 10.1007/978-1-62703-239-1_2, 23296649.
96. Hasty P, Sharp ZD, Curiel TJ, Campisi J. mTORC1 and p53: clash of the gods?. Cell Cycle 2013, 12(1):20-25. 10.4161/cc.22912, 3570511, 23255104.
97. Rufini A, Tucci P, Celardo I, Melino G. Senescence and aging: the critical roles of p53. Oncogene 2013, Epub ahead of print.
98. Blagosklonny MV. Tumor suppression by p53 without apoptosis and senescence: conundrum or rapalog-like gerosuppression?. Aging 2012, 4(7):450-455. 3433931, 22869016.
99. Ousset M, Bouquet F, Fallone F, Biard D, Dray C, Valet P, Salles B, Muller C. Loss of ATM positively regulates the expression of hypoxia inducible factor 1 (HIF-1) through oxidative stress: role in the physiopathology of the disease. Cell Cycle 2010, 9(14):2814-2822. 10.4161/cc.9.14.12253, 20676049.
100. Cam H, Easton JB, High A, Houghton PJ. mTORC1 Signaling under hypoxic conditions is controlled by ATM-dependent phosphorylation of HIF-1α. Mol Cell 2010, 40(4):509-520. 10.1016/j.molcel.2010.10.030, 21095582.
101. Freedman SJ, Sun Z-YJ, Poy F, Kung AL, Livingston DM, Wagner G, Eck MJ. Structural basis for recruitment of CBP/p300 by hypoxia-inducible factor-1 alpha. Proc Natl Acad Sci U S A 2002, 99(8):5367-5372. 10.1073/pnas.082117899, 122775, 11959990.
102. Xenaki G, Ontikatze T, Rajendran R, Stratford IJ, Dive C, Krstic-Demonacos M, Demonacos C. PCAF is an HIF-1alpha cofactor that regulates p53 transcriptional activity in hypoxia. Oncogene 2008, 27(44):5785-5796. 10.1038/onc.2008.192, 2664615, 18574470.
103. Roe JS, Kim H, Lee SM, Kim ST, Cho EJ, Youn HD. p53 Stabilization and transactivation by a von hippel-lindau protein. Mol Cell 2006, 22(3):395-405. 10.1016/j.molcel.2006.04.006, 16678111.
104. Pelletier J, Dayan F, Durivault J, Ilc K, Pecou E, Pouyssegur J, Mazure NM. The asparaginyl hydroxylase factor-inhibiting HIF is essential for tumor growth through suppression of the p53-p21 axis. Oncogene 2012, 31(24):2989-3001. 10.1038/onc.2011.471, 22002313.
105. Ashcroft M, Taya Y, Vousden KH. Stress signals utilize multiple pathways to stabilize p53. Mol Cell Biol 2000, 20(9):3224-3233. 10.1128/MCB.20.9.3224-3233.2000, 85616, 10757806.
106. Koumenis C, Alarcon R, Hammond E, Sutphin P, Hoffman W, Murphy M, Derr J, Taya Y, Lowe SW, Kastan M, et al. Regulation of p53 by hypoxia: dissociation of transcriptional repression and apoptosis from p53-dependent transactivation. Mol Cell Biol 2001, 21(4):1297-1310. 10.1128/MCB.21.4.1297-1310.2001, 99582, 11158315.
107. Koshikawa N, Maejima C, Miyazaki K, Nakagawara A, Takenaga K. Hypoxia selects for high-metastatic Lewis lung carcinoma cells overexpressing Mcl-1 and exhibiting reduced apoptotic potential in solid tumors. Oncogene 2006, 25(6):917-928. 10.1038/sj.onc.1209128, 16247470.
108. Hockel M, Schlenger K, Aral B, Mitze M, Schaffer U, Vaupel P. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res 1996, 56(19):4509-4515.
109. Cleven AHG, van Engeland M, Wouters BG, de Bruine AP. Stromal expression of hypoxia regulated proteins is an adverse prognostic factor in colorectal carcinomas. Cell Oncol 2007, 29(3):229-240.
110. Cleven AH, Wouters BG, Schutte B, Spiertz AJ, van Engeland M, de Bruine AP. Poorer outcome in stromal HIF-2 alpha- and CA9-positive colorectal adenocarcinomas is associated with wild-type TP53 but not with BNIP3 promoter hypermethylation or apoptosis. Br J Cancer 2008, 99(5):727-733. 10.1038/sj.bjc.6604547, 2528150, 18728663.
111. O'Toole D, Couvelard A, Rebours V, Zappa M, Hentic O, Hammel P, Levy P, Bedossa P, Raymond E, Ruszniewski P. Molecular markers associated with response to chemotherapy in gastro-entero-pancreatic neuroendocrine tumors. Endocr Relat Cancer 2010, 17(4):847-856. 10.1677/ERC-09-0204, 20570957.
112. Tan EY, Yan M, Campo L, Han C, Takano E, Turley H, Candiloro I, Pezzella F, Gatter KC, Millar EK, et al. The key hypoxia regulated gene CAIX is upregulated in basal-like breast tumours and is associated with resistance to chemotherapy. Br J Cancer 2009, 100(2):405-411. 10.1038/sj.bjc.6604844, 2634728, 19165203.
113. Maeda K, Chung YS, Ogawa Y, Takatsuka S, Kang SM, Ogawa M, Sawada T, Sowa M. Prognostic value of vascular endothelial growth factor expression in gastric carcinoma. Cancer 1996, 77(5):858-863. 10.1002/(SICI)1097-0142(19960301)77:5<858::AID-CNCR8>3.0.CO;2-A, 8608475.
114. Andersen S, Donnem T, Stenvold H, Al-Saad S, Al-Shibli K, Busund L-T, Bremnes RM. Overexpression of the HIF hydroxylases PHD1, PHD2, PHD3 and FIH are individually and collectively unfavorable prognosticators for NSCLC survival. PLoS One 2011, 6(8):e23847. 10.1371/journal.pone.0023847, 3161788, 21887331.
115. Henze A-T, Riedel J, Diem T, Wenner J, Flamme I, Pouyseggur J, Plate KH, Acker T. Prolyl hydroxylases 2 and 3 act in gliomas as protective negative feedback regulators of hypoxia-inducible factors. Cancer Res 2010, 70(1):357-366. 10.1158/0008-5472.CAN-09-1876, 20028863.
116. Baas IO, Hruban RH, Offerhaus GJ. Clinical applications of detecting dysfunctional p53 tumor suppressor protein. Histol Histopathol 1999, 14(1):279-284.
117. Khromova NV, Kopnin PB, Stepanova EV, Agapova LS, Kopnin BP. p53 hot-spot mutants increase tumor vascularization via ROS-mediated activation of the HIF1/VEGF-a pathway. Cancer Lett 2009, 276(2):143-151. 10.1016/j.canlet.2008.10.049, 19091459.
118. Baba Y, Nosho K, Shima K, Irahara N, Chan AT, Meyerhardt JA, Chung DC, Giovannucci EL, Fuchs CS, Ogino S. HIF1A Overexpression is associated with poor prognosis in a cohort of 731 colorectal cancers. Am J Pathol 2010, 176(5):2292-2301. 10.2353/ajpath.2010.090972, 2861094, 20363910.
119. Fondevila C, Metges JP, Fuster J, Grau JJ, Palacín A, Castells A, Volant A, Pera M. p53 and VEGF expression are independent predictors of tumour recurrence and survival following curative resection of gastric cancer. Br J Cancer 2004, 90(1):206-215. 10.1038/sj.bjc.6601455, 2395306, 14710231.
120. Oh SY, Kwon H-C, Kim S-H, Jang JS, Kim MC, Kim KH, Han J-Y, Kim CO, Kim S-J, Jeong J-S, et al. Clinicopathologic significance of HIF-1alpha, p53, and VEGF expression and preoperative serum VEGF level in gastric cancer. BMC Cancer 2008, 8:123. 10.1186/1471-2407-8-123, 2397429, 18452596.
121. Gryko M, Pryczynicz A, Guzinska-Ustymowicz K, Kamocki Z, Zareba K, Kemona A, Kedra B. Immunohistochemical assessment of apoptosis-associated proteins: p53, Bcl-xL, Bax and Bak in gastric cancer cells in correlation with clinical and pathomorphological factors. Adv Med Sci 2012, 57(1):77-83.
122. Wang J, Biju MP, Wang M-H, Haase VH, Dong Z. Cytoprotective effects of hypoxia against cisplatin-induced tubular cell apoptosis: involvement of mitochondrial inhibition and p53 suppression. J Am Soc Nephrol 2006, 17(7):1875-1885. 10.1681/ASN.2005121371, 16762987.
123. Brown JM. Exploiting the hypoxic cancer cell: mechanisms and therapeutic strategies. Mol Med Today 2000, 6(4):157-162. 10.1016/S1357-4310(00)01677-4, 10740254.
124. Fardel O, Lecureur V, Guillouzo A. The P-glycoprotein multidrug transporter. Gen Pharmacol 1996, 27(8):1283-1291. 10.1016/S0306-3623(96)00081-X, 9304397.
125. Tiwari AK, Sodani K, Dai C-L, Ashby CR, Chen Z-S. Revisiting the ABCs of multidrug resistance in cancer chemotherapy. Curr Pharm Biotechnol 2011, 12(4):570-594. 10.2174/138920111795164048, 21118094.
126. Doublier S, Belisario DC, Polimeni M, Annaratone L, Riganti C, Allia E, Ghigo D, Bosia A, Sapino A. HIF-1 activation induces doxorubicin resistance in MCF7 3-D spheroids via P-glycoprotein expression: a potential model of the chemo-resistance of invasive micropapillary carcinoma of the breast. BMC Cancer 2012, 12:4. 10.1186/1471-2407-12-4, 3262753, 22217342.